These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Results of the treatment of myeloma with a vincristine-melphalan combination]. Roux H; d'Omezon Y; Gaborit P; Eisinger F; Serratrice G Rev Rhum Mal Osteoartic; 1979; 46(7-9):443-8. PubMed ID: 315613 [TBL] [Abstract][Full Text] [Related]
5. "Protracted pulse" chemotherapy for refractory myeloma: a preliminary report. Manoharan A Eur J Haematol; 1990 Nov; 45(5):274-5. PubMed ID: 2261956 [No Abstract] [Full Text] [Related]
6. Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone. Snigurowicz J; Kraj M; Rostkowska J; Maj S; Mariańska B; Mendek E; Roszkowski S; Kilian Z; Kołakowski L Arch Immunol Ther Exp (Warsz); 1981; 29(2):145-53. PubMed ID: 7030265 [No Abstract] [Full Text] [Related]
7. [Value of successive chemotherapy in multiple myeloma of bone. Prospective study over 4 years]. Bataille R; Morlock G; Rosenberg F; Lopitaux R; Blotman F; Sany J; Ciurana AJ; Rampon S; Bussière JL; Simon L; Serre H Rev Rhum Mal Osteoartic; 1980 Feb; 47(2):77-82. PubMed ID: 7361063 [TBL] [Abstract][Full Text] [Related]
8. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039 [TBL] [Abstract][Full Text] [Related]
9. [Chemotherapy of multiple bone myeloma. Historical and present day aspects. (Second part) (author's transl)]. Bataille R; Morlock G; Rosenberg F; Sany J; Serre H Sem Hop; 1979 Sep 18-25; 55(31-32):1377-82. PubMed ID: 228415 [TBL] [Abstract][Full Text] [Related]
10. The current status and future prospects of treatment for multiple myeloma. Durie BG; Salmon SE Clin Haematol; 1982 Feb; 11(1):181-210. PubMed ID: 6176381 [No Abstract] [Full Text] [Related]
11. [Four cases of therapy-related leukemia in multiple myeloma]. Natori K; Izumi H; Kaneko K; Ishihara S; Nagase D; Fujimoto Y; Kato M; Umeda M; Kuraishi Y Gan To Kagaku Ryoho; 2007 Jan; 34(1):121-4. PubMed ID: 17220686 [TBL] [Abstract][Full Text] [Related]
13. VAMP followed by high dose melphalan and autologous bone marrow transplantation for multiple myeloma. McElwain TJ; Gore ME; Meldrum M; Viner C; Judson IR; Malpas JS Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():109-12. PubMed ID: 2697419 [TBL] [Abstract][Full Text] [Related]
14. [Myelofibrosis following a hyposecreting myeloma treated by vincristine, melphalan]. Schneider M; Cassuto JP; Duplay H; Viguier E; Lesbats G Nouv Presse Med; 1979 Sep; 8(35):2831-2. PubMed ID: 503814 [No Abstract] [Full Text] [Related]
15. [Treatment of Kahler's disease]. Foa J; Carcassonne Y Sem Hop; 1976 Jan; 52(3):165-71. PubMed ID: 186874 [No Abstract] [Full Text] [Related]
16. [Therapy of multiple myeloma. Study of hospital patients: 81 cases in 16 years' observation]. Monti G; Cereda UG; Pessina E; De Micheli N; Grisetti GC; Invernizzi F Minerva Med; 1983 Feb; 74(5):155-63. PubMed ID: 6828250 [TBL] [Abstract][Full Text] [Related]
17. [Prognosis of Kahler's disease in patients treated and not treated with alkylating agents (apropos of 45 cases)]. Saporta L; Hugon C; Rondier J; Bontoux D; Delbarre F Rev Rhum Mal Osteoartic; 1972 Jan; 39(1):11-8. PubMed ID: 5079686 [No Abstract] [Full Text] [Related]
18. [Results of combined treatment of advanced forms of multiple myeloma with vincristine, melphalan, cyclophosphamide and prednisone (VMCP) and with vincristine, doxorubicin, cyclophosphamide and prednisone (VDCP)]. Robak T; Krykowski E; Płuzańska A; Olszańska-Skorek T; Urbańska-Ryś H; Polkowska-Kulesza E; Błasińska-Morawiec M; Mazurowa A Pol Tyg Lek; 1983 Apr; 38(16):481-4. PubMed ID: 6579509 [No Abstract] [Full Text] [Related]
19. Multiple myeloma and acute leukemia associated with alkylating agents. Kyle RA; Pierre RV; Bayrd ED Arch Intern Med; 1975 Jan; 135(1):185-92. PubMed ID: 1053891 [TBL] [Abstract][Full Text] [Related]